An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

77 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-10-31

Study Completion Date

2013-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate tolerability of darunavir (PREZISTA) or etravirine (INTELENCE) in patients infected with human immunodeficiency virus type 1 (HIV-1) who are naïve to these medications and in patients who have experienced tolerability issues on their current or prior combination antiretroviral therapy (cART). The tolerability is evaluated by switching the patients from their previous or current combination antiretroviral therapy (cART) to either darunavir or etravirine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

NCT00460746

HIV

COMPLETED PHASE3

Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.

NCT00849160

HIV-1 Infection HIV Infections

COMPLETED PHASE3

Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects

NCT02404233

HIV Positive

UNKNOWN PHASE4

Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts

NCT01928407

HIV-1 Infection Immunosuppression-related Infectious Disease

COMPLETED PHASE4

A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista

NCT01741831

Acquired Immune Deficiency Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open label (all people know the identity of the intervention.), multicenter (study conducted at multiple sites), observational study (individuals are observed for certain outcomes) of darunavir and etravirine in patients infected with HIV-1 who are naïve to these medications and who have experienced tolerability issues on their current or prior combination antiretroviral therapy (medicines used for treatment of HIV). PREZISTA is indicated for naïve HIV patients (someone who has never used HIV drugs) and treatment-experienced HIV patients and INTELENCE is indicated for treatment-experienced patients who have failed prior therapy and have HIV-1 strains resistant to multiple antiretroviral agents (HIV-1 strains are able to survive the exposure of the multiple antiretroviral agents), including Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). In this study patients will receive either darunavir (PREZISTA) or etravirine (INTELENCE) and physician selected optimized background agents (other antiretroviral medicines), as permitted by the local formulary and supported by the current Canadian Product Monograph. 90 patients will participate in this study (75 Patients planned for the darunavir group and 15 patients planned for the etravirine group). The total duration of the study will be 24 weeks. Safety and tolerability will be evaluated at screening (14 days prior to Day 1), baseline (patient's medical status before any treatment or research is done) at Day 1, Week 4, Week 12 and Week 24. Tolerability will be evaluated using HIV Symptom Distress Module (HIV-SDM) also referred to as the HIV Symptom Index (HSI) which is a self-completed questionnaire to evaluate symptoms and measure the presence and bothersomeness of side effects commonly seen with HIV and antiretroviral treatment over the last 4 weeks (20 questions about all symptoms which the patient might have had during the past four weeks). Higher scores indicate the presence of more symptoms and/or a greater degree of distress related to the 20 symptoms. In HIV-SDM data is collected to see the benefit of switching to either darunavir or etravirine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Immunodeficiency Virus (HIV)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

darunavir (PREZISTA)

PREZISTA co-administered with 100 mg ritonavir as per Canadian Product Monograph. (Observational Study)

darunavir (PREZISTA)

Intervention Type DRUG

Form = tablet, route = oral, Units = mg, number = 800 administered once daily

ritonavir

Intervention Type DRUG

Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily

etravirine (INTELENCE)

INTELENCE co-administered with other antiretroviral medicinal products as per Canadian Product Monograph (Observational Study)

etravirine (INTELENCE)

Intervention Type DRUG

Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily

Other antiretroviral medications

Intervention Type DRUG

Given as per Canadian Product Monograph

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

darunavir (PREZISTA)

Form = tablet, route = oral, Units = mg, number = 800 administered once daily

Intervention Type DRUG

etravirine (INTELENCE)

Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily

Intervention Type DRUG

ritonavir

Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily

Intervention Type DRUG

Other antiretroviral medications

Given as per Canadian Product Monograph

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a documented HIV-1 infection
* Have 1 or more significant symptoms with at least grade 2 toxicity on the Division of AIDS Toxicity "DAIDS grading scale" on current or prior combination antiretroviral therapy (cART) regimen (current or prior cART including regimens consisting of 2 Nucleoside reverse transcriptase inhibitors (NRTIs) and a third agent with the exception of darunavir or etravirine)
* Have stable response to current cART ie, have an HIV-plasma viral load \[number of virus in blood\] at screening \<400 copies/mL (undetectable) or last plasma viral load on prior regimen within the previous 6 months \<400 copies/mL)
* Must not have resistance to Primary HIV protease inhibitor medicines

Exclusion Criteria

* Has been Infected with HIV-2 - Has received previous treatment with darunavir or etravirine or non-HAART (Highly Active Antiretroviral Therapy) regimen
* Has had prior virologic failure to 2 or more regimens or single virologic failure on prior cART
* Has a documented resistance to darunavir and etravirine
* Is currently using any drug contraindicated in the current Canadian Product Monograph for darunavir or etravirine

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No